Table 4.

Factors associated with virologic suppression among children treated with LPV/r for more than 6 months

	HR*	95% CI	p-value	HR**	95% CI	p-value
Male sex	0.92	[0.66,1.28]	0.610	0.96	[0.63,1.47]	0.851
Residence outside of Panama City	1.43	[1.00,2.03]	0.048	1.93	[1.19,3.14]	0.008
Initiation of LPVr > 1 year	0.79	[0.53,1.18]	0.250	0.62	[0.34,1.13]	0.116
PMCT	1.00	[0.77,1.31]	0.989	1.18	[0.80,1.73]	0.402
Therapy prior to LPVr:
Mono/dual	0.85	[0.57,1.28]	0.442	0.65	[0.38,1.12]	0.120
HAART	1.15	[0.75,1.75]	0.519	0.94	[0.55,1.58]	0.805
Baseline viral load prior to LPVr
< 5,000				REF	REF	REF
5,000 to < 10,000				1.24	[0.35,4.32]	0.738
10,000 to < 100,000				0.68	[0.38,1.24]	0.210
> 100,000				0.37	[0.21,0.66]	0.001

HR= hazard ratio for suppression; HR > 1 indicates faster suppression., LPV/r= Lopinavir/ritonavir, PMCT= Prevention of mother-to-child-transmission, HAART= Highly active antiretroviral therapy

^*n= 207 children who initiated LPV/r-based HAART and had virologic follow-up (at least one subsequent viral load). Excludes two children with unknown place of residence.

^**n= 129 children who initiated LPV/r-based HAART, had virologic follow-up, and had a baseline viral load obtained prior to initiation of LPV/r